Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor

Journal of Thrombosis and Thrombolysis

Volumn 15, Issue 1, 2003, Pages 19-23

  Li, You Fu ^a   Spencer, Frederick A ^a   Becker, Richard C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Plasmin; Tissue factor pathway inhibitor

Indexed keywords

ALTEPLASE; HEPARIN; PLASMIN; PLASMINOGEN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DRUG EXPOSURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; UMBILICAL VEIN;

CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS; PEPTIDE HYDROLASES; PLASMIN; RECURRENCE; TISSUE PLASMINOGEN ACTIVATOR; UMBILICAL VEINS;

EID: 0242552231     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026136216869     Document Type: Article

References (25)

1. Granger CG, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction: A review. Drugs 1992;44:293-325.
2. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
3. Wilson SH, Bell MR, Rihal CS, et al. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001;141:704-710.
4. Zijlstra F, Hoorntje JC, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-1419.
5. Merlini PA, Ardissino D, Bauer KA, et al. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina. Blood 1995;86:3327-3332.
6. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
7. Broze GJ, Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-112.
8. Hansen JB, Svensson B, Olsen R, et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000;83:937-943.
9. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: The role of bifunctional coagulation cofactor. Thromb Res 1985;40:351-358.
10. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988;85:6687-6691.
11. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that the endothelium is the principle site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873.
12. Lupu C, Lupu F, Hennehy U, et al. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995;15:2055-2062.
13. Hampton YR, Koning A, Wright R, Rine J. In vivo examination of membrane protein localization and degradation with green fluorescent protein. Proc Natl Acad Sci USA 1996;93:828-833.
14. Simionescu M, Simionescu N. Endothelial transport of macromolecules: Transcytosis and endocytosis. Cell Biol Rev 1991;25:1-80.
15. Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation in to caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304.
16. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394-400.
17. Valentin S, Ostergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin: Evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinolysis 1992;3:221-222.
18. Hansen J-B, Svensson B, Olsen R, et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000;83:937-943.
19. Hajjanr, Acharya SS. Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci 2000;902:265-271.
20. Nagase H. Activation mechanism of matrix metalloproteinase. Biol Chem 1979;254:2296-2302.
21. Li A, Wun TC. Proteolysis of surface TFPI by plasmin: Effect on TFPI activity. Thromb Haemostas 1998;80:423-427.
22. Ott I, Malcouvier V, Schöming A, Neumannn FJ. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 2002;105:279-281.
23. Schaefer AI, Mars AK, Ware JA, Johnson PC, Rittenhouse SE, Saltzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986;78:73-79.
24. Griffin JT, Cochran LHG. Recent advances in the understanding of contact activation reactions. Semin Thromb Hemost 1979;5:254-273.
25. Weitz JI, Cruickshank MK, Thong B, et al. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988;82:1700-1707.